Healtheuniverse, Inc (HLUN) Fair Value & Analysis
Healthcare · US · Market cap $11.8K
Healtheuniverse, Inc
HLUN · US
Fair value as of: Jul 29, 2026
From 12 valuation models · updated 13 days ago
A solid business, currently priced close to our fair value.
What matters now
- The price sits close to our fair value, market and models broadly agree here, little valuation tension.
- Our model range runs from $0.0001 (bear) to $0.0001 (bull), base $0.0001. The closer the price sits to the lower half, the larger the margin of safety.
- Quality 58/100 (solid quality) with medium evidence: read the verdict with care.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 29, 2026.
How to read this chart
60‑month range $0.0001 – $0.0120 · the $0.0001 price screens below the $0.0001 fair value. Dashed = 300-day average. As of Jul 29, 2026.
Analysis
Healtheuniverse, Inc (HLUN) currently trades at $0.0001, while our model-based Fair Value estimate is $0.0001, implying the stock looks roughly 0.0% fairly valued today. The Quality Score stands at 58/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium), always confirm before acting.
Over the trailing twelve months, Healtheuniverse, Inc generated revenue of $482K at a net margin of 8.9%. Revenue declined 51.8% year over year. The stock trades on a trailing P/E of 0.1. Fundamentals as of Jul 29, 2026
The share trades near its 52-week high. For context, the median of 10 Healthcare peers we cover trades at -43% fair-value upside, at 0%, HLUN screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 12 models by family
Widest divergence: DCF Models ($0.0001) versus DCF Models ($0.0001). Highest evidence: Residual Income (76).
Notify me when HLUN reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 29, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 60 · Market factors (momentum, volatility) 50
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Healtheuniverse, Inc., a biotechnology development company, engages in the research, development, and commercialization of biopharmaceutical, biomedical, nutraceutical, and cosmeceutical products.
Full company description
Healtheuniverse, Inc., a biotechnology development company, engages in the research, development, and commercialization of biopharmaceutical, biomedical, nutraceutical, and cosmeceutical products. The company develops stem cell and regenerative medicine therapies utilizing non-embryonic adult stem cells for use in plastic and reconstructive surgery, orthopedic surgery, vascular surgery, cardiac surgery, and wound care. It also provides consulting services to various businesses in the areas of marketing, business organization, and raising capital for business ventures. The company was founded in 2001 and is headquartered in Covina, California.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2002 – FY2005 · reported fiscal years
Healtheuniverse, Inc reported revenue of $525K in FY2005 versus $3.6K in FY2002, a compound +427.3%/yr. Reported net income was $88.3K in FY2005.
Watch HLUN: get an alert when its fair value changes →
Peer Group
Biotechnology · 605 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Biotechnology median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 29, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | $486.03 | $278.78 | -43% |
| Regeneron Pharmaceuticals, Inc REGN | $664.45 | $594.40 | -11% |
| Samsung Biologics Co 207940 | 1,368,000 KRW | 1,091,384 KRW | -20% |
| Celltrion, Inc 068270 | 175,800 KRW | 76,325 KRW | -57% |
| WuXi Biologics (Cayman) Inc 2269 | HK$39.54 | HK$30.42 | -23% |
| Innovent Biologics, Inc 1801 | HK$86.70 | HK$19.66 | -77% |
| Sino Biopharmaceutical Limited 1177 | HK$5.26 | HK$3.36 | -36% |
| RemeGen Co 688331 | ¥134.45 | ¥23.19 | -83% |
| ALTEOGEN Inc 196170 | 276,500 KRW | 44,444 KRW | -84% |
| Biocon Limited BIOCON | ₹440.70 | ₹57.36 | -87% |
Compare Healtheuniverse, Inc with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Healtheuniverse, Inc (HLUN) overvalued or undervalued?
What is the fair value of HLUN?
What is the quality score of HLUN?
What is the revenue of Healtheuniverse, Inc (HLUN)?
What is the net profit margin of HLUN?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Healtheuniverse, Inc and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.